ESCO2

Across TCGA pan-cancer cohorts, ESCO2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of ESCO2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ESCO2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ESCO2 is over-expressed in tumor.

HNSC, BLCA, and LUAD are the cancer types where ESCO2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ESCO2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+1.086	<.001	12	view →
BLCA	Male	All	+1.614	<.001	11	view →
LUAD	Male	II,III,IV	+1.606	<.001	11	view →
KIRP	All	III,IV	+1.013	<.001	11	view →
KIRC	Male	All	+0.536	<.001	11	view →
LUSC	Female	II,III,IV	+2.101	<.001	9	view →
UCEC	All	III,IV	+2.678	<.001	8	view →
STAD	Female	All	+2.035	<.001	8	view →
LIHC	Male	All	+0.665	<.001	8	view →
COAD	All	II,III,IV	+0.752	<.001	7	view →
BRCA	All	III,IV	+1.823	<.001	6	view →
CHOL	Male	All	+1.456	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

ESCO2–HNSC

Open the HNSC breakdown →